Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month
State-of-the-art facility brings next-generation imaging and minimally invasive neurointerventional capabilities to Eastern India
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
